Vasili Lendel, MD
Interventional Cardiology · Little Rock, ARNPI 1720104516
Payments from drug & device makers
Across 418 payments — averaging $493.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endologix LLC$78K
- Cardiovascular Systems Inc.$49K
- Abbott$36K
- Shockwave Medical, Inc$24K
- M.a. Med Alliance S.A.$11K
- Boston Scientific$1K
- plus $7K from 26 others
What the payments were for
- Consulting fees$14,41317%
- Speaking & faculty fees$56,27065%
- Travel & lodging$4461%
- Food & beverage$14,96717%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endologix LLC | 31 | $77,876 |
| Cardiovascular Systems Inc. | 42 | $48,815 |
| Abbott | 50 | $36,411 |
| Shockwave Medical, Inc | 77 | $23,606 |
| M.a. Med Alliance S.A. | 4 | $11,115 |
| Boston Scientific | 27 | $1,395 |
| Asahi Intecc USA, Inc. | 37 | $1,021 |
| Inari Medical, Inc. | 9 | $932 |
| Abiomed | 8 | $726 |
| Johnson & Johnson | 23 | $497 |
| Livanova USA, Inc. | 4 | $406 |
| E.r. Squibb & Sons, L.L.C. | 24 | $403 |
| Avinger Inc. | 10 | $390 |
| Penumbra, Inc. | 5 | $386 |
| AstraZeneca | 16 | $343 |
| Biotronik Inc. | 6 | $296 |
| Mercator Medsystems, Inc. | 1 | $288 |
| BD | 2 | $249 |
| W. L. Gore & Associates, Inc. | 2 | $243 |
| Lexicon Pharmaceuticals, Inc. | 9 | $153 |
| Pfizer | 8 | $129 |
| Novartis | 8 | $127 |
| Janssen Scientific Affairs, LLC | 1 | $124 |
| Bard Peripheral Vascular, Inc. | 1 | $122 |
| Novo Nordisk | 6 | $102 |
| Teleflex LLC | 1 | $98 |
| Opsens Inc. | 1 | $73 |
| Cordis US CORP. | 1 | $23 |
| Merck | 1 | $22 |
| Medtronic | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Peripheral Orbital Atherectomy System$26,521
- Diamondback Peripheral$25,829
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$22,616
- FLOWTRIEVER CATHETER, S$943
- Impella$546
- CT THROMBECTOMY SYSTEM KIT$479
- Bullfrog$288
- Indigo System$251
- RotarexS 6 F x 135 cm$249
- CROSSBOSS$246
- Orsiro Mission$243
- PANTHERIS$217
- GORE VIABAHN VBX Balloon Expandable Endo$152
- HORNET$150
- ASAHI PTCA Guide Wire Minamo$147
- COROFLOW$146
- LifeSPARC System$146
- EKOSONIC$145
- TandemHeart$143
- Diamondback Coronary$141
How this compares
$206,410 in reported general payments places this provider in the 95th percentile of 89 interventional cardiology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 746 | $702,068 |
| XareltoRivaroxaban | 770 | $689,680 |
| EntrestoSacubitril/Valsartan | 285 | $288,012 |
| VyndamaxTafamidis | 12 | $268,144 |
| FarxigaDapagliflozin Propanediol | 171 | $132,828 |
| Repatha SureclickEvolocumab | 75 | $62,594 |
| MultaqDronedarone Hcl | 39 | $47,196 |
| BrilintaTicagrelor | 38 | $29,916 |
| JardianceEmpagliflozin | 32 | $22,648 |
| ClopidogrelClopidogrel Bisulfate | 1,521 | $15,492 |
| Dofetilide | 69 | $11,725 |
| Ranolazine ErRanolazine | 102 | $11,294 |
| Metoprolol Succinate | 885 | $11,038 |
| Prasugrel Hcl | 161 | $10,257 |
| Clonidine | 60 | $8,553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $129 | $970,212758 claims |
| Johnson & JohnsonXarelto | $497 | $689,680770 claims |
| NovartisEntresto | $127 | $288,012285 claims |
| AstraZenecaFarxiga, Brilinta | $343 | $162,744209 claims |
| Sanofi-aventis U.S. LLCMultaq | $11 | $47,19639 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $153 | $6,78911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 89 interventional cardiology providers in Arkansas.
Other interventional cardiology in Little Rock
- Gaurav DharLittle Rock$793K
- Ernesto Ruiz-RodriguezLittle Rock$499K
- Vijay RajaLittle Rock$106K
- Thomas WattsLittle Rock$79K
- Stephen BroughtonLittle Rock$34K
- Mahesh Anantha NarayananLittle Rock$26K
- Aravind RaoLittle Rock$17K
- Patrick TobbiaLittle Rock$14K
- Subhi AlarefLittle Rock$13K
- Hamza RayesLittle Rock$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.